TUBB3基因对NSCLC病人术后辅助化疗预后评价

VALUE OF TUBB3 GENE IN EVALUATION OF PROGNOSIS OF NSCLC PATIENTS UNDERGOING POSTOPERATIVE ADJUVANT CHEMOTHERAPY

目的探讨Ⅱ~ⅢA期非小细胞肺癌（NSCLC）组织3型β微管蛋白（TUBB3）基因表达及其与术后辅助化疗效果相关性。方法Ⅱ~ⅢA期非小细胞肺癌病人88例,均进行根治性手术及术后采用长春瑞滨＋顺铂方案化疗,应用SYBR荧光实时定量PCR技术检测肿瘤组织中TUBB3mRNA表达水平,并分析TUBB3基因表达水平与病人预后的关系。结果 TUBB3mRNA低表达者无瘤生存期与高表达者比较,差异无显著意义（P〉0.05）;总生存期比较,差异有显著性（χ2=5.205,P〈0.05）。Cox多因素分析显示,TUBB3mRNA高表达（RR=0.453,95%CI：0.267~0.768,P〈0.05）、肿瘤分期（RR=1.629,95%CI：1.158~2.293,P〈0.05）为病人独立的不良预后因素。结论 TUBB3mRNA可能是预测Ⅱ~ⅢA期NSCLC术后辅助化疗疗效及预后评估的有效指标,检测TUBB3mRNA表达有助于NSCLC病人的个体化治疗。

Objective To explore the correlation between the expression of β-tubulin-Ⅲ （TUBB3） gene and the efficacy of postoperative adjuvant chemotherapeutic in non-small cell lung cancer （NSCLC） with stage Ⅱ -Ⅲ A of TNM. Methods Eighty eight patients with stage Ⅱ -Ⅲa NSCLC underwent radical surgery and postoperative chemotherapy with vinorelbine--cisplatin （NP）. The levels of TUBB3 mRNA expression in tumor tissue was detected, by SYBR real-time fluorescence quantitative PCR, and its association with patient prognosis was analyzed. Results There was no significant difference between low and high-ex pression with regard to cancer-free survival （P〉0.05）, hut there was＇difference in terms of overall survival （t =5.205,P〈0.05）. Cox multivariate analysis showed high TUBB3 expression （RR=0.453,95% CI：0.267-0.768,P〈0.05） and TNM stage （RR= 1.629,95%CI：1.158--2.293,P〈0.05） were independent factors for poor prognosis. Conclusion The TUBB3 mRNA may be a level of significance to predict the efficacy of postoperative chemotherapy for patients with stage Ⅱ -ⅢA NSCLC and assess their prognosis, the detection of TUBB3 rnRNA is conducive to individualized therapy for patients with NSCLC.